LB793: A Phase 1, Open-Label, Single Ascending Dose Study in Healthy Subjects of the Safety, Tolerability and Pharmacokinetics of ASLAN004, a Novel IgG Anti-IL-13 Receptor Alpha 1 Inhibitor

    August 2021 in “ Journal of Investigative Dermatology ”
    L. Lee, H. Hajireen, Alan Ward, C. Firth

    We don't know much about this study yet.

    We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.
    Discuss this study in the Community →